The Center for Disease direction a...

The Center for Disease direction and Prevention (CDC) released recommendations forward the screening of newborns for cystic fibrosis. The report includes an evaluation of the benefits and risks of this pattern of screening. It also provides recommendations in succession how to effectively implement screening programs for states that elect to routinely screen newborns for cystic fibrosis. The recommendations were published in the October 15 2004 recommendations and reports series of Morbidity and Mortality Weekly Report. The abounding report is available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5313a1.htm. An editorial discussing these guidelines also appears in this issue of American Family Physician onward page 1482.

In November 2003 the CDC and the Cystic Fibrosis Foundation (CFF) cosponsored a workshop to examine the benefits and risks of newborn screening for cystic fibrosis. The three objectives of the workshop were: (1) to review and evaluate the scientific evidence onward the benefits and risks of newborn screening for cystic fibrosis; (2) to review screening, diagnostics, and follow-up touchs when making decisions about newborn screening for cystic fibrosis; and (3) to disseminate information about patterns and best practices for states that select to adopt newborn screening for cystic fibrosis.

Evidence at handed at the workshop supported the clinical utility of this pattern of screening. Demonstrated benefits include improved growing and cognitive development, reduced hospitalizations, and improved survival. Risks include psychosocial validitys for carrier children and their families, and position of children to infectious agents end person-to-person transmission in clinical settings.

Background

Cystic fibrosis is the next to the first most common life-shortening, childhood-onset inherited disorder in the United States, behind sickle confined apartment disease. Annually, about 1,000 bodily substances in the United States are diagnosed with cystic fibrosis. In 1979 a standard to measure the levels of immunoreactive trypsinogen (which is substantially elevated in newborns with cystic fibrosis) in dried progeny spots was introduced and made universal newborn screening for cystic fibrosis possible. This example is now the basis for newborn screening protocols.

In 15 to 20 percent of children with cystic fibrosis, the first symptom is meconium ileus; adverse issues include malnutrition, lung disease, and mortality. Because meconium ileus is diagnostic for cystic fibrosis, screening does not increase early detection for these children.

Early recognition of cystic fibrosis based onward symptoms often is difficult because the majority of symptoms are not specific to the condition. Therefore, affected children are oftentimes diagnosed with celiac disease, regimen allergies, asthma, or bronchitis. The events of misdiagnosis include unnecessary diagnostic ordeals and hospitalizations, multiple office visits, price to the health care method and anxiety for parents.

The median age at diagnosis for all living bodys with cystic fibrosis in the United States is 53 month The overall median age at diagnosis includes infants diagnosed shortly after birth based on newborn screening, prenatal screening, family history, or the air of meconium ileus. The median age at diagnosis based forward signs and symptoms other than meconium ileus is 145 month compared with 02 month in those with meconium ileus and 05 month for those receiving newborn screening. A diagnosis based upon symptoms is associated with a more than double greater risk of medical complications before diagnosis than a diagnosis resulting from screening. Adverse psychosocial results for the child's family also may be derived during the delay between the appearance of cystic fibrosis-related symptoms and diagnosis.

In 1999 a CFF consensus panel unfolded a new case definition for cystic fibrosis based forward the following criteria: the appearance of at least one characteristic phenotypic feature or a history of cystic fibrosis in a sibling or a positive newborn screening example together with laboratory evidence of an abnormality in the gene that regulates expression of the cystic fibrosis transmembrane conductance regulator protein as documented on (1) elevated sweat chloride concentrations, (2) identification of sum of two units mutations associated with cystic fibrosis, or (3) in vivo demonstration of characteristic abnormalities in ion transport across the nasal epithelium. Sweat testing can be performed accurately forward most infants at two to three weeks of age, if it were not that not all infants have sufficient quantities of sweat for reliable testing. Although a sweat chloride horizontal of 60 mEq per L is diagnostic of cystic fibrosis, infants with cystic fibrosis oftentimes have initial sweat values of 30 to 59 mEq by L.

In 2000 approximately 400000 children (10 percent) born in the United States were veiled for cystic fibrosis, and this number was awaited to increase to 800,000 in 2004 Screening protocols for cystic fibrosis are listed in the accompanying table.